SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " Drugs " 589 found 🔀 AI-powered Shuffle
Goodbye obesity, hello Ozempic: GLP-1 politics
The rise of Ozempic and GLP-1 drugs reveals how body politics, beauty standards, class and desirability shape ideas of the American body.
Guns, drugs, AI, budget cuts join traditional maladies at public health forum
A daylong public health forum in Baltimore on Tuesday touched on health challenges that likely aren't found in any medical textbook: gun violence, artificial intelligence, social media and "the ravages of Washington" under the Trump administration.
Billionaire Mark Cuban’s 5-step plan to make healthcare affordable targets drug middlemen’s ‘contractual terrorism’
The Cost Plus Drugs cofounder told Texas lawmakers that insured patients are often better off paying cash—and laid out five fixes built around price transparency.
Would subsidizing weight-loss drugs make health care fairer?
GLP-1 medicines such as Ozempic, Wegovy and Mounjaro have transformed the treatment of obesity, but access to them in Australia increasingly depends on something much less medical: whether you can afford ...
Scientists finally uncover why statins can cause muscle pain
Scientists have uncovered a surprising reason why statins, the widely prescribed cholesterol-lowering drugs that help prevent heart attacks and strokes, can sometimes cause muscle pain, weakness, and even severe muscle damage. Using advanced imaging technology, researchers discovered that statins can attach to a crucial protein in muscle cells and force open a channel that normally controls calcium flow. This causes calcium to leak continuously, potentially damaging muscle tissue.
GLP-1 drugs may protect kidney health in people with bipolar disorder
Mayo Clinic researchers found that GLP-1 receptor agonists, medications widely used for diabetes and weight management, were associated with a lower risk of dialysis or kidney transplantation in adults with bipolar disorder and chronic kidney disease.
GLP-1 Drugs and Mental Health: Effects on Depression and Anxiety
GLP-1 receptor agonists affect pathways involved in mood, appetite, and reward, prompting research into their potential benefits for depression, substance use disorders, and binge eating. Psychiatric treatment benefits remain unproven, while conflicting observational findings and reassuring trial evidence require careful interpretation.
LIFE-HEALTH-GLP-1S-ALCOHOL-FILEPIC-DMT
A Philadelphia Veterans Affairs doctor is leading a national trial testing whether GLP-1 drugs could help patients with alcohol use disorder.
Brenda Vaccaro makes rare comment about ending engagement to Michael Douglas for Don Stroud
“I fell in love with somebody else, and I knew it,” the “Drugstore Cowboy” actress admits in a new interview.
RFK Jr. proposes FDA look the other way on unproven peptides, report says
FDA scientists said none of the popular drugs have been proven safe or effective.
Stand Up for Science Traces the Surprising Story Behind Ozempic and Related Drugs in the Latest 'Traces
Venom from a desert lizard, a hormone that vanishes in minutes & 40 years of persistence: the “overnight” weight loss drug revolution wasn’t overnight at all
After stopping weight-loss drugs, people given a procedure kept about 80% of lost weight
In a post hoc analysis, 32% of Revita participants were weight-stable or lost more, versus 18% with sham; one-year results are anticipated in Q1 2027.
Who gets Alzheimer's drugs? Race, vulnerability and health status shape access
The first disease-modifying drugs for Alzheimer's disease offer patients the ability to slow cognitive decline by targeting amyloid plaques in the brain. But a new study suggests that not all patients ...
Why your health insurance is dropping GLP-1 coverage
Coverage for these anti-obesity drugs was finally becoming more common. Not anymore.
Trump administration advances plan for peptide drugs favored by RFK Jr.
Peptides are essentially unproven, unapproved, injectable drugs.
Weight-loss drugs may fight 7 serious health problems before the pounds even come off
GLP-1 medications like semaglutide and tirzepatide are repairing joints, calming inflammation, and protecting vital organs before any weight loss occurs.
FAA Unveils New Tool to Gauge Fitness to Fly
MedGuide is an online, interactive resource that enables users to search medical conditions, prescriptions drugs and over-the-counter medications to determine whether a medication is acceptable for safety-related duties and whether an initial or subsequent-dose waiting period applies.
Ex-Florida congressman Matt Gaetz accused in suit of sex trafficking young women
The lawsuit alleges the two women were supplied with drugs, traveled across state lines and were paid to have sex with men, including Gaetz.
Ozempic and Wegovy linked to rare risk of sudden vision loss
Popular diabetes and weight loss drugs such as Ozempic and Wegovy have been linked to a slightly increased risk of a rare condition that can cause sudden, potentially permanent vision loss. Although the risk remains very low, Rutgers researchers say the findings warrant attention as millions of people turn to GLP-1 medications.
Finnish study finds poor oral health increases jawbone necrosis risks in breast cancer patients
Antiresorptive drugs, which reduce bone breakdown, are an important part of treatment for breast cancer that has spread to the bones. However, their use can be associated with osteonecrosis of the jaw (MRONJ), a condition in which bone tissue in the jaw dies.
Meet Iris Shen, the 17-year-old Texas student who used clams as a model for testing blood-cancer drugs, found a drug combination that slowed tumor growth, and won a $150,000 Regeneron Science Talent Search prize
Iris Shen, a 17-year-old student from The Woodlands, Texas, has earned third place and a $150,000 award in the 2026 Regeneron Science Talent Search for an unusually creative approach to blood-cancer research. Instead of relying only on conventional laboratory models, Shen tested a potential cancer drug in clams to determine whether these animals could serve as an animal model for blood-cancer drug discovery.
Great Women of Science: Ada Yonath, the Nobelist exemplifying perseverance
She was told she was chasing the impossible. She persisted through poverty, skepticism, and 25,000 failed attempts. In the end, Ada Yonath unlocked one of biology’s most elusive structures: the ribosome, transforming our understanding of how antibiotics work and paving the way for drugs that can overcome antibiotic resistance. Her story is not only one of scientific brilliance, but of extraordinary perseverance.
Weight-Loss Drugs for Kids Under 10? The World Health Organization Shares Its Recommendation
The World Health Organization (WHO) just released its first global guidelines on treating obesity in children and adolescents, and its stance on weight-loss drugs for children under 10 is a firm no. T...
Particle Engineering Takes Center Stage as Formulation Science Pushes Drugs Toward the Clinic
A January 2027 special issue of the Journal of Pharmaceutical Investigation will spotlight how particle engineering and formulation science translate laboratory innovations into manufacturable drug dosage forms.
Scientists win chemistry Nobel for discoveries about mirrored molecules that led to many drugs
Portraits of Henri Kagan and Kenso Soai are shown on the screen as they are awarded the 2026 Nobel Prize in Chemistry, at the Royal Swedish Academy of Sciences in Stockholm, Sweden, on Oct. 7, 2026. Photo: (Fredrik Sandberg/TT News Agency via AP)By ADITHI RAMAKRISHNAN, KOSTYA MANENKOV and STEFANIE DAZIO STOCKHOLM (AP) — Scientists Henri B. Kagan and Kenso Soai...
Popular weight loss drugs linked to a surprising fingernail problem
Popular GLP-1 weight loss drugs, such as Ozempic and Wegovy, have been linked to unexpectedly high rates of nail detachment, hair loss, and scalp inflammation, with some problems occurring several times more frequently among users. Researchers found that weight loss alone could not fully explain the differences, suggesting there may be more to these overlooked symptoms.
How ‘people power’ and business transformed medicine, but created a whole new set of risks
We’re seeing what happens when consumer demand collides with commercial interests for drugs including GLP-1s, psychedelics and testosterone. It’s a huge shift.
A surprisingly simple way to relieve knee arthritis pain without pills or surgery
A surprisingly simple change in how you walk could help relieve knee arthritis pain and even slow joint damage. In a year-long clinical trial, researchers found that adjusting the angle of a person's foot while walking reduced osteoarthritis pain by an amount comparable to medication, without requiring drugs or surgery. Even more promising, MRI scans revealed that participants who adopted the personalized walking technique experienced slower deterioration in a marker of knee cartilage health.
Ongoing lawsuits allege GLP-1s can cause serious harm. But we don't know how often
Scant data about serious adverse effects makes it harder to answer scientific and legal questions about how often the drugs might cause serious harm like blindness or pancreatitis.
Some People Taking Ozempic-Like Drugs Are Reporting Their Fingernails Detaching
An unexpected link worth investigating.
Trump bucks and the politics of mailing checks
The checks started going out last week, nearly one million of them, and mostly to battleground states. With a return address for the U.S. Treasury and a letter enclosed signed by President Donald Trump, these one-time checks for $500 were ostensibly government rebates for Obamacare enrollees who overpaid. In the accompanying letter, however, Trump attacks his predecessor and talks about his record in office on an important issue he’s not polling well on, which makes it seem more like the most expensive political mailer in U.S. history. The average piece of direct mail costs between 30 cents and $3, according to Mail Processing Associates, a print, mail, and fulfillment company. At $500 a pop plus roughly 50 cents each to issue the paper check, the cost of Trump’s healthcare mailer sent to more than 950,000 enrollees comes in at more than $475 million. Trump’s midterm healthcare message “For years, the Biden Administration overcharged you to fund the operation of HealthCare dot gov,” Trump wrote in the letter. “That money belongs to hard-working Americans, not the Government, and now, I am returning it to you!” In the letter, Trump makes false and misleading claims about his administration’s record on healthcare costs, an issue Democrats have a 20 point advantage on over Republicans, according to a recent poll from KFF, a nonpartisan health policy think tank. Trump touts his administration’s TrumpRX program, which he claims is “delivering massive discounts.” However, new research from KFF found that of a selection of drugs available on the TrumpRX platform, just five were the lowest price, while 13 were the highest price. Trump also falsely claims in the letter that he’s fighting to lower healthcare costs. In reality, average monthly premium payment costs for enrollees rose 58% under Trump while marketplace sign-ups declined 5%, per KFF. Under Trump’s One Big Beautiful Bill Act, it’s estimated 10 million more Americans will be uninsured by 2034. You get a check and you get a check and you get a check Trump’s long promised cash outs to his fans, from his days as a casino operator and gameshow host to his presidency. During the early days of the COVID-19 pandemic in 2020, the first Trump administration made the unprecedented move to put Trump’s name on checks that went out under the CARES Act (notably the $500 refund checks this time around don’t feature Trump’s name). Ever since, Trump’s been chasing that high. In his second term, Trump’s promised more stimulus that never arrived, like refund checks from DOGE cuts and tariffs, while he said at his party’s convention last month that he’d give out $5,000 checks to everyone if Republicans win in November. In reality, DOGE overstated its cost cutting and Trump’s government actually now spends more than former President Joe Biden’s, while Trump’s tariffs actually grew the trade deficit. His proposal for $5,000 checks would add about $1.2 trillion to the national debt. The problem is there’s no money to give. These $500 checks — plus $90 Medicare rebate checks also going out as well as $250 deposited this week in some Trump Accounts for kids courtesy Dell Technologies CEO Michael Dell and his wife Susan — represent the closest Trump’s going to get to making good on his promise to deliver cash fast. And the checks seem especially targeted. Though the $500 checks went out to enrollees in one of 30 states that use the federal HealthCare dot gov marketplace, a Reuters review found 71% of the payments, or $339 million, went to enrollees in 13 states that have the most competitive elections for governor and U.S. Senate. Most Americans don’t buy it Could Trump bucks sway the election? An Economist-YouGov poll found 57% of U.S. adults doubt Trump will deliver on his promise for $5,000 checks, compared to 21% who do. “I’m waiting on my DOGE check and I’m still waiting on my tariff check,” one 2024 Trump voter who’s since turned on him told a recent focus group. “It felt like kind of trying to buy people’s votes, which honestly felt like in elementary when the class president was like, hey we’re going to take you to the water park if you vote for me. It’s like, I don’t think it works like that.” But for voters in swing states who got a check, it could still matter. One survey published in 2022 found receiving a physically personalized check in the mail during the pandemic was associated with a much greater self-reported likelihood of voting for Trump in 2020, and those gains mainly came from out partisans. The issue for Trump comes if these checks are mostly going to Obamacare enrollees whose premiums have gone up by more than just $500 since he took office and who view the money as something like a bribe before the election rather than an actual long-term solution to lowering household costs. Spending $500.50 per mailer would be absurd as a normal campaign expenditure, but since Trump’s checks and letter are a government rebate, his campaign and super PAC didn’t have to spend a dime and he got out his message regardless. If enough voters in key states are swayed by the one-time payment, it could prove to be the best $0 the Trump campaign spent. Subscribe [ ](https://www.yellopolitics.com/p/why-independent-candidates-are-making) [ Why independent candidates are making independence central to their brand ](https://www.yellopolitics.com/p/why-independent-candidates-are-making) Hunter Schwarz · Oct 6 [ Read full story ](https://www.yellopolitics.com/p/why-independent-candidates-are-making) [ ](https://www.yellopolitics.com/p/these-designers-and-grocery-nerds) [ These designers and grocery nerds will brand Mamdani’s NYC grocery stores ](https://www.yellopolitics.com/p/these-designers-and-grocery-nerds) Hunter Schwarz · Oct 2 [ Read full story ](https://www.yellopolitics.com/p/these-designers-and-grocery-nerds) Trump wants to turn his first-ever golf course into a government course for presidents
Sami Inkinen, Virta Health CEO: A Fortt Knox Update
Virta Health CEO Sami Inkinen said the company posted its first-ever profitable quarter — Q2 2026, on cash-flow and EBITDA — after a post-2021 down round, part of a "Project Independence" push to self-funding. In conversation with Jon Fortt, he casts GLP-1 drugs as a tailwind: with nutrition, Virta says patients lose a third more weight (20% vs 15%) and sustain 85% of the weight loss a year after stopping, saving ~$5,600 per diabetes patient yearly. Virta serves ~800 employers and plans.
The Math Singularity Is Here, and Science May Be Next
OpenAI has released an extraordinary body of mathematical work produced by an unreleased frontier model: 722 manuscripts spanning 372 research families across fields including number theory, complexity theory, and mathematical physics. Each result required, on average, the equivalent of roughly three hours of ChatGPT Pro reasoning. A New Era of Discovery We may be witnessing the beginnings of a “math singularity”: a point at which machine-generated discovery accelerates beyond humanity’s ability to independently reproduce, verify, or fully absorb it. If frontier models can generate hundreds of meaningful results in the time it takes a human researcher to investigate one, the constraint will no longer be producing new mathematics. It will be our capacity to validate, interpret, and integrate it. This does not make mathematicians obsolete. It changes their role. They may increasingly serve as guides, critics, and meaning-makers. Increasingly, they will decide which questions matter, determining which results can be trusted, and explaining why they are important. Mathematical insight may become abundant, while human judgment becomes more valuable than ever. Mathematics May Be Only the Beginning Every scientific discipline could eventually experience a similar acceleration. AI systems could generate and test hypotheses, connect findings across specialized fields, and explore possibilities at a scale no human research community could match. In medicine, imagine models identifying overlooked disease mechanisms, designing drugs and clinical trials, personalizing treatments, or discovering cures in months rather than decades. In materials science, AI could help create better batteries and cleaner industrial processes. In climate science, it could accelerate advances in energy, forecasting, and carbon removal. In biology, it could uncover relationships hidden across enormous genomic and molecular datasets. The result would not simply be faster research. It could expand the frontier of what is scientifically possible. The New Bottleneck Scientific discovery, however, is not the same as scientific progress. A medical breakthrough must still survive laboratory testing, clinical trials, regulatory scrutiny, manufacturing constraints, and real-world deployment. As machine-generated ideas multiply, the bottleneck may shift from producing breakthroughs to validating them safely and translating them into practice. We may soon have more hypotheses than laboratories can test, more drugs than clinical trials can evaluate, and more mathematical results than experts can review. That imbalance will require better systems for automated verification, reproducible research, prioritization, peer review, and collaboration between AI and domain experts. The importance of OpenAI’s work is not merely the number of manuscripts produced. It offers a glimpse of a world in which intelligence can explore thousands of intellectual paths in parallel. If ideas cease to be scarce, humanity’s defining challenge will be deciding which are true, which matter, and how to turn them into progress. The math singularity is not the end of human inquiry. It is the beginning of a new kind—one in which machines expand the frontier of knowledge and humans decide where it should lead. Subscribe Share Leave a comment
GLP-1s: the science behind today’s weight-loss drugs
The medicines reshaping obesity treatment grew out of research into how the body handles a meal. Long before weekly weight-loss injections became familiar, scientists were studying signals that travel from the intestine to the pancreas, helping it release insulin when nutrients arrive.
Scientists win chemistry Nobel for discoveries about mirrored molecules that led to many drugs
Scientists Henri B. Kagan and Kenso Soai won the Nobel Prize in chemistry for untangling mysterious mirror images in molecules, a discovery that has been used to develop countless drugs.
People on weight-loss drugs report fingernails falling off as researchers uncover surprising link
Nail discoloration was reported by 46% of GLP-1 users versus 17% of non-users, while scalp inflammation accompanied hair loss in most medication users studied.
HOMETOWN HEALTH: How to keep the weight off after stopping GLP-1 drug
Many people rapidly regain weight after stopping GLP-1 weight loss drugs
GLP-1 Drugs? Surgery? WHO Issues Guidelines For Obesity In Children
The World Health Organization (WHO) released its first-ever guidelines to address how clinicians should manage obesity in children and adolescents, which
New global guidelines warn against obesity drugs for children under 10
Care should focus on healthy eating and exercise, not medicines such as weight-loss injections, says the World Health Organization
WHO endorses lifestyle changes over GLP-1 drugs in child obesity fight
The World Health Organization on Wednesday recommended diet, exercise and counseling over popular weight-loss drugs in its first global guidelines addressing rising obesity among younger children.
Brazil: Lessons from a Disaster
By Antonio Martins (Outras Palavras) Defeats become deeper and more prolonged when we misunderstand what caused them, avoid correcting course, and embrace “solutions” that only compound our mistakes. Lula’s government and the Brazilian left suffered a disaster in Sunday’s election. Contrary to every poll, the president finished the first round 2.2 million votes behind Flávio Bolsonaro—and, more significantly, 3.4 million votes below his total four years ago, when the machinery of the state was working against him and in favor of his opponent. His vote share declined in 98 percent of Brazil’s municipalities. The PL, the main party of the far right, elected 121 deputies and 28 senators, becoming the largest caucus in both houses of Congress. The parties aligned with the Centrão—Brazil’s bloc of transactional center-right parties—were somewhat diminished, but will still hold roughly 250 seats in the Chamber of Deputies and 35 in the Senate. That will make it easier to assemble the majorities needed to amend the Constitution or impeach Supreme Federal Court justices. If elected, Flávio Bolsonaro could appoint four members of the Court, substantially altering its internal balance of power. What produced these results? How can the far right be prevented from consolidating them into a prolonged political hegemony? And what is the essential change of direction the left now needs? Explaining the Disaster Across the commercial media and the exuberant chaos of digital platforms, interpretations are multiplying. Some focus on specific episodes: Lula’s absence from the Globo debate, his very close relationship with Alexandre de Moraes, or his emphasis on issues supposedly remote from most people’s everyday concerns, such as rare earth minerals. Among the more systemic interpretations, three seem especially questionable. One argues that the principal defeat was not the left’s, since its congressional representation declined only slightly. The decisive movement captured at the ballot box, according to this view, was a shift within the right itself—from the more moderate and transactional forces of the Centrão toward the more ideological and radicalized forces of the PL and Novo. A second interpretation holds that the nature of electoral and political processes has changed. The material interests and aspirations of society, it argues, no longer play the central role they once did; they have given way to forms of subjective self-identification that the left has yet to understand. And a third concludes that, because of these two developments, we should expect a political winter: a prolonged period in which the far right and the broader right dominate Brazilian political life. There are important elements in all three interpretations. The problem lies in what they deny or leave out: Lula’s third government was a small-bore government. It offered the majorities that elected it neither a clearly better life nor reasons to believe again in politics and its power to transform society. These failures flowed from two fatal accommodations, which I will examine below. As a result, the government suffered a slow but steady erosion of support. And, as has happened in so many Western countries, it gave the far right the opportunity to present itself as anti-system and to benefit from popular frustration and distress. The interpretation that emphasizes the migration of votes from the center-right and traditional right toward the far right has been advanced, among others, by the courageous journalist Leonardo Sakamoto. In his UOL column on Monday, October 5, he highlights the miserable behavior of the traditional conservative parties. Over the past four years, they repeatedly joined forces with the “neo”-fascists, helping to “normalize” them—a criticism that could equally be directed at almost the entire corporate media. Believing they could use the far right as a stepping stone, they instead ended up partly devoured by it. This was especially true in the Senate, where the PL’s gain of 13 senators and Novo’s gain of two came at the expense of the PSD, which lost nine; the MDB, which lost two; the PSDB, which lost two; and the PP, which lost one. Sakamoto’s observation is accurate and necessary, but it leaves uncomfortable questions unanswered. Why did the erosion of the Centrão benefit the far right rather than, for example, producing growth for the left—as has happened so many times before, both in Brazil and elsewhere? The answer is not difficult. Throughout its four years in office, Lula’s third government was almost invariably associated with the Centrão. Here lies its first accommodation: accepting the limits imposed by conservative institutions; avoiding, as much as possible, any attempt to strain those limits through popular pressure; and believing only in the modest changes that could be squeezed through openings in Congress. The failure of the campaign to end the six-day workweek is emblematic. Lula could have electrified the presidential race by pairing it with a popular campaign for passage of the measure. Instead, he chose to place his hopes in the hands of Senate president Rodrigo Alcolumbre. He generated no mass mobilization, did not force his opponents onto an uncomfortable defensive, and won no victory. In September 2025, the government squandered the greatest of its many opportunities to shake up conservative power in Congress. Popular opposition to the so-called Shielding Amendment—which, if approved, would have restricted criminal proceedings against members of Congress—brought crowds into the streets, mobilized primarily by artists and social movements. This opened the possibility for a broader political education: a campaign that could begin exposing the limits and dysfunctions of Brazil’s political system while putting Bolsonaro’s movement on the defensive for its predictable support of political privilege. The amendment was defeated. But the executive branch then backed away from the fight. It remained associated with an institutional world widely seen as corrupt, elitist, and indifferent to ordinary people’s struggles. In doing so, it forfeited its credibility as a vehicle for the protest vote. On Sunday, it reaped the bitter fruits. Are We Doomed? Taking a different approach from Sakamoto, the philosopher Moysés Pinto Neto and other writers have drawn attention, in their first analyses of October 4, to the fragmentation of the public sphere produced by Big Tech platforms. Through their algorithms, these platforms present each person with a different view of social reality. As a consequence, it becomes much harder to identify common material problems and demands—for example, the fight for labor rights or for a properly funded public health system. Voters no longer embrace such demands, these authors argue, because they no longer see themselves as part of a collective. Instead, they tend to value the identities assigned to them by neoliberal subjectivity—the role of the entrepreneur, for example. On this interpretation, the left’s possible error lies in clinging to outdated illusions. Moysés’s warning is highly relevant and resonates with arguments such as Naomi Klein and Astra Taylor’s “Apocalyptic Fascism and the Billionaires’ Bet.” Unlike a century ago, the far right no longer promises a radiant future. It concentrates instead on resentment—especially that of young men. “They belong to a generation that fears it may never own a home, but compensates with the pleasure it gets from constantly provoking progressives online. Convinced their future has been stolen, they share memes romanticizing historical authoritarian regimes,” the authors write. But Moysés seems to confuse this danger with inevitability. He fails to see that the left’s answer cannot be adaptation. On the contrary, it must strengthen the possibility of politics as collective action. Nor does he recognize that precisely such a reversal is already becoming possible in some of the most promising mobilizations of the twenty-first century: the election, at the end of 2025, of the young Muslim Zohran Mamdani as mayor of New York, on a platform centered on the intensely material fight for an affordable city; the Left Party’s victory in Berlin two weeks ago, built around the demand to expropriate private real-estate corporations; and the very recent wave of demonstrations in Spain—including an occupation of Madrid’s Puerta del Sol—in which tens of thousands of young people mobilized by the Tenants’ Union have demanded limits on rents. By putting itself in the straitjacket of the “fiscal framework” in the first months of 2022, Lula’s third government adopted the second fatal accommodation of its term. Faced with conservative institutions and a country devastated by four years of Bolsonaro, increased public investment was the government’s remaining weapon for offering a more dignified life to the majority and forging an anti-conservative pact with them. The same state that disburses 1 trillion reais a year to enrich a small class of rentiers could instead spend money to extend the Family Health Strategy to every Brazilian, at a cost of 30 billion reais; provide full-day public schooling and childcare to all adolescents and children—and, especially, relief to their mothers; achieve universal sanitation while cleaning up polluted urban rivers; multiply metro systems; begin transforming the urban peripheries; and undertake many other urgently needed projects. In April 2023, an article in Outras Palavras warned that the fiscal framework could “shrink the Lula government and preserve the forces that condemn the country to inequality and regression.” A year later, another article showed that restraints on public spending were strangling policies vital to ordinary people and undermining the president’s popularity. In November 2024 came a reality check, in the form of the government’s humiliating defeat in the municipal elections. Even then, the fiscal lock was neither removed nor loosened. On the contrary: throughout the government’s four years, fiscal restraint remained central to its political narrative. The administration proudly proclaimed that it had “put the state’s accounts in order,” without grasping either how misleading that phrase was—given the payment of 1 trillion reais in interest—or how badly the message was hurting it politically. Lula finally woke up in September 2026. The increase in Bolsa Família benefits, after four years of being frozen; the announcement that anti-obesity drugs would be offered through Brazil’s public health system; and the ban on online betting showed that the state has the power to act decisively on behalf of the majority when those in government are willing to confront obstacles. The huge marches that closed the campaign in Fortaleza, Salvador, Rio de Janeiro, and São Paulo on the eve of October 4 showed how such initiatives can mobilize activists and the broader public. But it was too late—and too little to change the outcome of the first round. History has not ended The possibility of a turnaround in the three weeks leading up to November 25 cannot be ruled out. It will not be simple or easy. Lula must not only make up a deficit of 2.2 million votes; he must also offset the movement of voters who backed other right-wing candidates in the first round, most of whom are likely to move toward Flávio Bolsonaro. Pulling that off will require a broad, grassroots effort to win over voters, potentially reinforced by new initiatives from Lula. The coming hours and days will be decisive. If Bolsonaro’s movement also wins the presidency, the result will create a high-risk situation for Brazilian sovereignty and democracy. The enormous challenges posed by such an outcome would require the left to reexamine, in depth and with a genuine willingness to engage in self-criticism, its political projects—or its lack of them—and its practices. But would that mean we are condemned to the long winter of far-right hegemony that some analyses are beginning to forecast? It is far too early to say, suggests a recent text by Álvaro García Linera, the thinker who served as vice president of Bolivia under Evo Morales. His central hypothesis is that this political current will prove short-lived. At a moment when the entire world is once again talking about sovereignty and protecting national economies, the far right offers a stale, recolonizing neoliberalism. Its submission to the United States is as blatant and pathetic as Flávio and Eduardo Bolsonaro’s overtures to Donald Trump. Its project amounts to something like every man for himself: greater inequality, capitalism without limits, devastation, and supremacism. Will it work? In the United States, just two years into his second term, Trump himself is reaching record levels of unpopularity and may be on the verge of losing Republican control of both the House and Senate in November. Every new beginning is difficult. Whatever the outcome of the second round, the defeats of October 4 show how profoundly the Brazilian left will have to rethink and rebuild. But just as it would be foolish to underestimate the seriousness of its mistakes, it would be equally foolish to conclude that rebuilding a political project is no longer possible. History has not ended. The times are moving faster than ever. Originally published in Portuguese by Outras Palavras. English translation by Eric Blanc; I’ve added the subtitles. More We can’t stop the far right at home or abroad without a revitalized labor movement, which is yet another reason why you should become a sustaining supporter of the Emergency Workplace Organizing Committee (EWOC) — one of US labor’s pivotal bright spots. Relatedly, Jacobin published a short piece of mine reflecting on a decade of Bernie Sanders inspiring a whole new generation of young worker organizers.
FT and Standard Chartered Book of the Year Award 2026
Contenders include titles on weight-loss drugs, AI weaponry and forecasting
FT and Standard Chartered Book of the Year Award 2026
Contenders include titles on weight-loss drugs, AI weaponry and forecasting
Health conference to cover GLP-1 drugs, hormone therapy, youth sports
The Area Health Education Center (AHEC) will host its 42nd Annual Update in Medicine Conference.
Doctors Should Keep an Eye on Your Mix of Medication. If They Don’t, You Should.
By Paula Span | KFF Health News Medications can snowball as we age. Pill organizers pile up. Prescriptions that are no longer necessary can mix with other drugs to create concerning side effects. “Once you get to six or seven prescription medications, you get a nearly 100% chance of some sort of ...
GE HealthCare to buy Sofie Biosciences for $945 million to strengthen radiopharma business
Medical device maker GE HealthCare said on Monday it would buy privately held Sofie Biosciences for $945 million in cash, in a move that strengthens its ability to manufacture and distribute PET imaging drugs.
Obesity Startup Ilant Health Bets Its Revenue On Better Patient Outcomes
Founder Elina Onitskansky's Ilant Health has raised over $22 million to pair weight loss drugs with dietitians, behavioral health and peer support.
Doctors Should Keep an Eye on Your Mix of Medication. If They Don’t, You Should.
There’s a term for reducing unnecessary or harmful drugs: “deprescribing.” Especially as patients age, experts say, it’s important to regularly review the medications they’re taking.
At San Francisco General, researchers are learning how to control HIV without drugs
Doctors at San Francisco General Hospital's famed AIDS clinic have shown the immune system can be primed to keep the virus in check — a promising advance just as U.S. funding cuts threaten future research.
The Science Behind a Simple Headache Trick People Swear By
A viral trend promoting the placement of hair claw clips on eyebrows has captivated millions seeking fast headache relief without prescription drugs. If you have spent any time scrolling social media lately, you have probably spotted people clamping plastic claw clips directly onto their faces. It looks like an eccentric comedy sketch, but videos demonstrating this unusual trick have racked up more than 9 million views. Desperate headache sufferers are flooding comment sections, calling the clip
Weight Loss Drugs Give Restaurants a New Hurdle: Diners Who Eat Less
Fewer orders and higher costs are squeezing restaurants big and small as people on the weight-loss drugs eat and drink less when dining out.
This week in health care policy: September 28 – October 2, 2026
Drug pricing CMS finalizes GLOBE pilot. On September 30, CMS finalized the Global Benchmark for Efficient Drug Pricing model, a program that ties Part B drug rebates to prices paid in 19 countries. It will cover physician-administered drugs in randomly selected communities throughout the US, representing about 25 percent of Part B beneficiaries. It runs […]
Health, AI Innovations Prompt Longevity Concerns
TIAA study examines the retirement implications of tech including AI and weight-loss drugs, and the need for lifetime income
Amazon, GoodRx target U.S. prescription subscribers as health insurance coverage slips
Amazon.com, GoodRx and other companies offering online subscriptions that charge a flat fee for prescription drugs and other health services are reaping the benefits of Americans looking to combat rising costs and dwindling health insurance options.
Rapid weight loss on popular drugs could ‘starve’ the brain, expert warns
Dr. Tommy Wood warns GLP-1 drugs like Ozempic and Wegovy can shrink brain tissue when caloric restriction cuts off vital energy the brain needs.
FDA seeks scientists and consumer representatives for advisory panels
The US Food and Drug Administration on Wednesday launched a nationwide effort to recruit scientists, medical experts and consumer representatives to its advisory committees, which advise the agency on drugs, vaccines and other regulated products.
Sugar Amplifies Damage Done to Gut Health by Antibiotics
/PRNewswire/ -- Eating sweets while taking antibiotics may worsen the harm done by the drugs to the normal community of bacteria in the gut, a new study found....
New Cancer Drugs Are Revolutionary. Why Don’t More Patients Get Them?
Targeted gene therapies are highly effective at stopping cancers, but the very abundance of the treatments, plus cost and sluggish change, are hindering access.
Drugs are widely used to sedate dementia patients. Her sons wanted to keep her off them
Potent sedating medications are often used on agitated people with dementia in long-term care facilities despite federal efforts to discourage them. A clash over whether to drug a Michigan woman illuminates the wrenching decisions families and guardians face.
‘Godzilla’ of weight-loss drugs could provide other important health benefits
Though not yet approved by any regulatory agency, Retatrutide could help improve blood sugar levels and reduce inflammation
Amazon, GoodRx target US prescription subscribers as health insurance coverage slips
Amazon.com , GoodRx and other companies offering online subscriptions that charge a flat fee for prescription drugs and other health services are reaping the benefits of Americans looking to combat rising costs and dwindling health insurance options.
After Failed Execution, Health Workers Say State’s Rules Flout Medical Ethics
The death penalty is legal in 27 states, and lethal injection is the primary method. That means involving medical professionals to store, test, and inject the drugs. After a botched execution in Tennessee, doctors and nurses there say medical professionals need to be removed from the process completely.
Guest article: When nutrition becomes an evidence-based intervention, capital follows
Health and nutrition positioning alone buys nothing. Investors want evidence that products work and a moat competitors can’t easily replicate
DEA Highlights the Integral Role of Forensic Science in Addressing the Synthetic Drug Crisis
As synthetic drugs continue to evolve and threaten American lives, DEA chemists and forensic science professionals play an essential role in helping the U.S. Drug Enforcement Administration identify emerging threats, connect evidence to investigations, and provide timely information that can save lives. From analyzing suspected fentanyl and other novel synthetic drugs to examining fingerprints and…
Could psychedelic therapy become NHS treatment for mental health?
Could hallucinogenic drugs become part of mainstream NHS care to treat depression?
Kodiak Sciences Stock Surges 125% After Late-Stage Drug Trial Success
The trial tested two experimental eye drugs, Zenkuda and tabirafusp-ted, for treating wet age-related macular degeneration.
Millions more people with overweight could benefit from GLP-1 drugs to protect heart health, study suggests
New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, makes a case for extending the indication for GLP-1 receptor ...
AEW's Brian Cage Defends PED Use
AEW star Brian Cage has acknowledged using performance-enhancing drugs, but maintains that it's quite possible to use them safely.
Weight loss drugs could help treat women’s reproductive health issues, experts say
Experts say weight loss drugs could help women struggling with PMOS.
Jury awards $11 million to family of mentally ill man killed by LAPD
Wilver Blanco, 42, was shot in 2024 after police were called to the Broadway-Manchester neighborhood for a report of man seen chasing an elderly man with a knife, possibly while under the influence of drugs.
Police: Driver was high when he crashed into Massena home business
A St. Lawrence County man was allegedly high on drugs when he drove a pickup truck into a house in Massena Thursday morning.
As pharmacies across Vermont close, North Star Health opens 3 new ones
SPRINGFIELD — In the era of independent pharmacy closures and ballooning drug costs, a new pharmacy that charges less for drugs seems counterintuitive, if not impossible. But that’s exactly what North Star Health, a Federally Qualified Health Center that operates medical clinics in Vermont and New Hampshire, did when it officially launched three new pharmacies […]
Opinion: Kobach's politics of tragedy underline our nation's immigrant crime double standard
When a native-born American commits a murder, we generally understand the concept of individuality perfectly well. We ask about motive, rage, domestic conflict, ideology, drugs, mental illness, opportunity or the peculiar facts of that person's life.
Ozempic-Like Drugs Linked to 11x Higher Vomiting Risk Under Anesthesia
Be honest with your anesthetist.
Mississippi health officials issue warning after deaths of two Ole Miss students
The Mississippi State Department of Health is urging people to avoid counterfeit pills and other unregulated drugs
South Korea’s weight-loss obsession and the health risks it brings
South Korean women face higher underweight rates than men, with experts warning that social pressure to be thin and weight-loss drugs may pose health risks.
As pharmacies across Vermont close, North Star Health opens 3 new ones
The pharmacies take advantage of the health center’s federal designation that allows them to pay less for drugs, charge patients lower costs and still meet their bottom line.
Vanderbilt Health study identifies drugs with potential to improve outcomes associated with preterm labor
A team of Vanderbilt Health investigators has identified drugs with previously unrecognized potential as treatments for preterm labor.
Hayden Panettiere death investigation reveals drugs found with star: Report
Blue pressed pills that tested positive for fentanyl were discovered near Hayden Panettiere following her fatal overdose, according to a newly released investigative report.
Hayden Panettiere's death was caused by the toxic effects of fentanyl and other drugs, ruled 'accidental'
The Greenville County Coroner's Office said that the 36-year-old's cause of death has been ruled as "toxic effects of fentanyl, 4-ANPP, Alprazolam, Methocarbamol and Quetiapine." The manner of death h...
Hayden Panettiere died from accidental overdose involving fentanyl, coroner says
A coroner has determined that actor Hayden Panettiere died from an accidental overdose of several drugs including fentanyl. The 36-year-old Panettiere was found unresponsive in an apartment in Greenville, South
Hayden Panettiere cause of death revealed: Report
The actress’ death was ruled an accident caused by the toxic effect of several drugs, including fentanyl.
Hayden Panettiere’s death was accidental and involved fentanyl, coroner says
A coroner has determined that actor Hayden Panettiere died from an accidental overdose of several drugs including fentanyl | WWL
Hayden Panettiere’s death was accidental and involved fentanyl, coroner says
A coroner has determined that actor Hayden Panettiere died from an accidental overdose of several drugs including fentanyl | 830 WCCO
Hayden Panettiere's death ruled accidental from drugs, including fentanyl: Coroner
Actress Hayden Panettiere’s death has been ruled accidental from drugs including fentanyl, according to the Greenville County Coroner’s Office in South Carolina.
MORNING BUSINESS REPORT: Seniors use weight loss drugs, Apple settlement, Disney trip deals
More seniors are using drugs like Ozempic, customers can claim part of an Apple settlement, and Disney offers promotional deals. Here's the Morning Business Report for Sept. 22.
Is 50 the new 60?
Subscribe TL;DR: Younger generations are showing signs of worse health compared to earlier-born cohorts at the same age This backward “drift” is showing up both in mortality risk and chronic disease Worsening trends in obesity and diabetes are the most consistent signals Taking the long view, we’ve made astonishing gains in health and life expectancy in the last century. Global average life expectancy has more than doubled from 32 years in 1900 to 73 years in 2024. (But don’t forget, there were still old people when life expectancy was 32). As people lived longer, they also generally lived healthier along the way. It turns out that avoiding things that can kill you early, like malnutrition and lots of childhood infections, also keeps you healthier later in life. In a classic 2004 paper, Finch and Crimmins proposed that cohorts of children who benefited from fewer early life infections had less lifetime exposure to inflammation and cardiovascular disease later in life, accelerating mortality improvements at older ages. Poor nutrition in the womb has also been linked to a higher risk of later chronic disease. The upshot is that improvements in childhood health can pay dividends many decades later. The combination of better living conditions (nutrition, sanitation) and medical advances (antibiotics, vaccines, blood pressure meds, etc) meant that people’s healthy lifespan generally expanded, even as they lived longer. Aging researchers call this best-case scenario “compression of morbidity”—meaning we delay the onset of disease and disability even faster than the years of life we are adding. During my 20+ year research career, we could generally bank on the idea that younger generations would not only live longer but also keep getting healthier along the way. “60 is the new 50” as they say… Enter “Generational Health Drift” Sadly, this expectation of steady progress may be changing. You’ve probably heard that US life expectancy gains have slowed to a crawl in the past couple of decades. Mortality improvements are also slowing (though less dramatically) in many other high-income countries (you can read more about that in a review paper I wrote here). Mortality is a very blunt health measure, but it is often a good barometer for the broader population health trends happening underneath. And we are now seeing that younger generations may be in worse health at similar ages compared to earlier born cohorts. My collaborator Prof. George Ploubidis at University College London coined this worsening health in more recently born cohorts “generational health drift.” “Generational health drift” is bad news on multiple fronts. Most obviously, we don’t want our health progress to go backward. But the timing is also bad, since our populations are aging. In demographic terms, “population aging” means that the proportion of the population at older ages (i.e >65 years) is increasing. Fun demography fact: Current population aging is not due to the recent declines in the birth rates making the news, but declines in fertility decades ago, after the “baby boom.” As baby boomers reach older ages, the smaller cohorts behind them mean the percentage of older adults will increase. For example, the share of the population age 65 and older in the US increased from 12.4% in 2004 to 18.0% in 2024. This story of population aging was written long ago. Many worry that population aging will put pressure on health care and pension systems. But if people reach older ages in better health than in years past, those fiscal pressures would be less dire than projected. Healthy older people can also continue to contribute to society in many valuable ways, including paid work, caregiving, community service….even high political office 🤷. On the flip side, if younger generations reach retirement age in worse health and with more disabling conditions, this could magnify the societal challenge of population aging. Evidence for worsening generational health A recent paper that I LOVED in the Proceedings of the National Academy of Sciences by Dr. Leah Abrams and colleagues examined which birth cohorts (aka generations) were behind worsening US mortality. Behold the Lexis diagram (cue swooning demographers). Calendar time is on the x-axis, age on the y-axis. Birth cohorts can be followed over time as they age on the diagonal lines moving up and to the right. This figure plots the year-on-year % change in all-cause mortality at a given age. Green shading indicates mortality improvements over time, white is stagnation, and gray shading indicates worsening mortality. Following the diagonal line for those born in 1950, you can see a noticeable shift from green to gray that follows this cohort for most of their lives. This gray shading shows generally worsening mortality for the 1950 to 1959 birth cohorts compared to their predecessors across all ages. Concerningly for my GenX and elder millennial peeps, there was also a deterioration in mortality for birth cohorts born in the 1970s and 1980s, visible as dark gray areas at ages 30 to 45 during the 2010s. While some of these mortality changes reflect specific shocks such as the opioid epidemic, most deaths still occur from major causes of death such as cardiovascular disease and cancer. For cancer, the gray in the top left corner of the figure below reflects the legacies of smoking for older cohorts, followed by a period of green with improvements in cancer mortality as smoking rates declined. But the white/gray shading in the bottom right corner highlights a stagnation and reversal of the cancer trends, with cohorts born around 1970 to 1985 experiencing worsening cancer mortality. This deterioration was most noticeable for colon cancer mortality, possibly linked to obesity or dietary factors. Not just dying more, but less healthy along the way. A recent paper by Dr. Laura Gimeno of University College London (of which I am a co-author), found evidence that more recently born cohorts in Great Britain have stagnating or worsening health. A stylized picture of what“generational health drift” might look like: The review paper found: Rates of childhood overweight and obesity were highest among Gen Z. Rates of diabetes in the 40s almost doubled from 3.1% among the Baby Boomers to 5.9% in Generation X. Gen Z reported higher rates of poor mental health in adolescence compared to earlier-born groups. These UK results are consistent with studies showing worsening health across generations in the US as well. A 2021 US study found that more recently born cohorts had worse biological markers (like blood pressure and blood sugar) than earlier generations at the same age. A separate 2022 study of Americans aged 50 and over found that more recently born generations had a higher number of chronic diseases, with younger age of disease onset. A 2024 Lancet paper found that in the US, women born in 1945 had 33% obesity prevalence at age 50, rising to 48.2% for women born in 1970 turning 50. So what’s going on, and can we turn it around? We don’t have a definitive answer for what’s causing the deteriorating health of younger cohorts, but circumstantial evidence points to worsening trends in obesity and diabetes in both the US and UK. Remember that cohort trends reflect lagged effects of early environments, and younger generations have faced both earlier onset and more severe obesity across their lifetimes. Despite these very concerning trends, the future is not set in stone. We’ve reversed poor generational health trends before: drops in smoking are a major reason cancer and heart disease deaths fell so dramatically in recent decades. GLP-1 drugs may finally turn the tide against rising rates of obesity and diabetes, though it is still early days. But things could also get worse…for example from a return to higher levels of childhood infectious diseases that can have a lasting impact on health. See for example: [ ](https://jenndowd.substack.com/p/dont-you-forget-about-measles-the) [ Don’t You Forget About Me(asles): The Virus That Erases Immune Memory ](https://jenndowd.substack.com/p/dont-you-forget-about-measles-the) Jenn Dowd, PhD · March 24, 2025 [ Read full story ](https://jenndowd.substack.com/p/dont-you-forget-about-measles-the) Even as an optimist, emerging data on the “generational health drift” has my full attention. For most of my research career, we took it for granted that each generation would be healthier than the last. But if present trends continue, **50 could be the new 60….**and Gen Z celebrities will soon look older than Paul Rudd :). Stay well, Jenn Share the Health! If you found this post useful, please share it with a friend. Share
Police search for possible source of drugs in death of Presley Gerber, Cindy Crawford's son
Presley Gerber, the supermodel's son with businessman Rande Gerber, died Sunday at a rehab facility at age 27.
What is ibogaine, and what does it treat?
Psychedelic drugs, once pushed to the fringes of medicine, are gaining serious attention within the Trump administration as potential treatment options for people with certain mental health conditions. And they could be getting closer to receiving approval from the US Food and Drug Administration.
Hayden Panettiere remembered at Malibu memorial service
Hayden Panettiere attends the Los Angeles premiere of Netflix's new film 'Blonde' at TCL Chinese Theatre on Sept. 13, 2022, in Hollywood, California. (Jon Kopaloff/Getty Images)Hayden Panettiere was celebrated over the weekend at a memorial service held in California, her representative confirmed to ABC News.Around 80 friends of the late Nashville star, who died on Aug. 16 at the age of 36, gathered in Malibu on Saturday to share "an evening of music, memories, laughter and tears."“We wanted to honor Hayden in the best way we knew how—with as much love as possible," Panettiere's representative, Kasey Kitchen, said in a statement with a group of the actress's friends, who jointly organized the memorial.The statement continued, "It was a beautiful and intimate ceremony where friends came together to celebrate her life and honor the beautiful, magnetic light and love she infused into the world.”Panettiere's Nashville co-star Connie Britton and other celebrities, including Evan Ross and Ruby Rose, were photographed attending the memorial.Panettiere died after she was found unresponsive and in cardiac arrest at a Greenville, South Carolina, apartment.The actress's official cause and manner of death have not yet been announced.An investigation into her death has expanded from South Carolina to Los Angeles, and investigators are focusing on the role drugs may have played in her death, sources told ABC News last week.Kitchen, Panettiere's representative, said in a statement on Sept. 15 that her death "remains under investigation pending toxicology results.""As we await the answers we are all seeking, may we also remember Hayden for the incredible legacy she leaves behind — the light she shined on mental health and postpartum depression, and the voice she gave to those who felt unseen and unheard," Kitchen said. "The answers we are all seeking will come."Copyright © 2026, ABC Audio. All rights reserved.
The Best Shampoos for Every Hair Need and Budget, According to Experts
From drugstore gems to salon splurges, these shampoos are worth a spot in your wash day routine.
Scientists create a needle-thin brain implant that can do three jobs at once
A new needle-thin brain implant can record neural activity, deliver drugs, and stimulate multiple brain regions using a single flexible fiber. Successful tests in mice suggest it could give scientists a more precise, less invasive way to study the brain and may eventually help treat neurological disorders such as epilepsy.
Scientists Discover New Compound That Burns Fat Without Killing Your Appetite
Unlike GLP-1 drugs, which suppress appetite and reduce energy intake, a newly identified molecular compound helps cells burn more energy without changing food intake or exercise and has shown promise in mouse models. The most successful new obesity drugs largely work by helping people eat less. Researchers at UC Berkeley are exploring a different strategy:
Trump announces all 50 states joining Medicaid drug pricing model
President Donald Trump announced that all 50 states will join a program to provide Most Favored Nation pricing for some Medicaid drugs. The administration claims this plan, called the Medicaid
Trump announces all 50 states joining Medicaid drug pricing model
President Donald Trump announced that all 50 states will join a program to provide Most Favored Nation pricing for some Medicaid drugs.
GW Global Health Expert: No ‘Magic Bullet’ for Malaria - Elimination Will Require a Combination of Tools
New review examines how vaccines, antimalarial drugs and mosquito-control measures could work together to accelerate progress toward a malaria-free world
Health insurers covered 112,000 fewer Mass. residents’ GLP-1 weight-loss drugs this year, report finds
Insurers restricted coverage for obesity after years of financial losses.
US Medicare Pricing Policies Could Drive Global Costs And Hinder Access Worldwide
A new modelling study suggests that US Medicare “Most-Favored-Nation” policies on drug prices would cut Medicare spending on brand name drugs, but potentially
US Medicare Pricing Policies Could Drive Global Costs And Hinder Access Worldwide
A new modelling study suggests that US Medicare “Most-Favored-Nation” policies on drug prices would cut Medicare spending on brand name drugs, but potentially
3 Common Drugs Older Adults Might Be Overusing
Not all older people need benzodiazepines, antibiotics, or daily aspirin — and taking them can carry increased risks.